Skip to content
Advertisement

FILE - This Friday, Oct. 10, 2008, file photo illustration shows Johnson & Johnson products, in Philadelphia. Johnson & Johnson is topping profit and revenue expectations for the first quarter partially on strong sales of its psoriasis treatment, Stelara.  The New Brunswick, N.J., company on Tuesday, April 16, 2019  posted profit of $3.75 billion, or $1.39 per share. Earnings, adjusted for amortization costs and research and development costs, were $2.10 per share, or 7 cents better that Wall Street expected, according to a survey by Zacks Investment Research. (AP Photo/Matt Rourke, File)

FILE - This Friday, Oct. 10, 2008, file photo illustration shows Johnson & Johnson products, in Philadelphia. Johnson & Johnson is topping profit and revenue expectations for the first quarter partially on strong sales of its psoriasis treatment, Stelara. The New Brunswick, N.J., company on Tuesday, April 16, 2019 posted profit of $3.75 billion, or $1.39 per share. Earnings, adjusted for amortization costs and research and development costs, were $2.10 per share, or 7 cents better that Wall Street expected, according to a survey by Zacks Investment Research. (AP Photo/Matt Rourke, File)

Featured Photo Galleries